二甲双胍对接受强化生活方式治疗的新诊断2型糖尿病合并非酒精性脂肪性肝病患者影响的随机对照试验:研究方案
本方案为单中心随机对照试验,拟将非酒精性脂肪性肝病(NAFLD)合并新诊断2型糖尿病(T2DM)患者按1:1:1随机分为三组,分别接受生活方式干预、二甲双胍500-2000 mg/日、或两者联合治疗12周,主要结局为血糖控制和脂肪肝严重程度从基线至12周随访的变化。
要点
- NAFLD与T2DM共存加速两者进展且预后不良,目前尚无糖尿病合并NAFLD的治疗共识。
- 该试验比较生活方式干预、二甲双胍单药及两者联合对血糖和脂肪肝严重程度的影响。
- 主要结局为基线至12周随访时血糖控制和脂肪肝严重程度的变化。
核心结论
- 该试验旨在阐明生活方式干预联合二甲双胍是否对NAFLD合并新诊断T2DM患者的血糖控制和延缓NAFLD进展具有协同效应。
研究设计与样本
- 单中心随机对照试验,通过电话访谈招募参与者,按1:1:1比例随机分配到三组。
- 三组分别接受生活方式干预(包括限制热量的饮食和运动治疗)、二甲双胍500-2000 mg/日、或两者联合治疗,疗程12周。
关键数值与推荐
- 主要结局为从基线至12周随访时血糖控制和脂肪肝严重程度的变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common chronic diseases. The coexistence of NAFLD and diabetes accelerates the progression of both and tends to induce bad prognosis. To date, lifestyle modification has been suggested as the first-line treatment for NAFLD patients. Some studies indicated that lifestyle modification could normalize glucose levels in newly diagnosed T2DM, but many individuals do not reach glycemic targets in practice using lifestyle modification alone. Considering the tight link between NAFLD and T2DM, metformin, a widely used drug in diabetic patients with a good safety profile, may be a possible treatment or control of NAFLD progression. There is no therapeutic consensus for the treatment of NAFLD patients with diabetes. Therefore, it is essential to elucidate the beneficial effects of lifestyle modification combined with metformin on glucose-lipid metabolism in the NAFLD population with newly diagnosed T2DM. METHODS: Participants will be recruited in this single-center, randomized clinical trial through telephone interview. All participants will be assigned randomly at a 1:1:1 ratio to three groups and treated with lifestyle modification including calorie-restricted dietary and exercise therapy, 500-2000 mg/day metformin, or treated with both lifestyle modification and 500-2000 mg/day metformin (the co-intervention group) for 12 weeks. The primary outcomes are changes in glycemic control and severity of fatty liver from baseline to 12 weeks of follow-up. DISCUSSION: This trial is designed to clarify whether lifestyle intervention combined with metformin has synergistic effects on glycemic control, attenuating the progression of NAFLD in NAFLD patients with newly diagnosed T2DM. TRIAL REGISTRATION: ChiCTR2300072031. Registered on 31 May 2023.
引用
- Chen K, Zhong C, Zhou L, et al. Randomized controlled trial of effects of metformin in NAFLD patients with newly diagnosed type 2 diabetes treated with an intensive lifestyle: a study protocol. Trials. 2025. PMID: 41174662. doi:10.1186/s13063-025-09191-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。